These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31562548)

  • 1. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
    Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
    Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.
    Babyshkina N; Vtorushin S; Zavyalova M; Patalyak S; Dronova T; Litviakov N; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
    Clin Exp Med; 2017 Aug; 17(3):383-393. PubMed ID: 27225751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
    Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
    Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
    Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
    PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
    Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
    Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
    Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
    Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Estrogen-Regulated
    Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
    Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
    Izadi P; Mehrdad N; Foruzandeh F; Reza NM
    Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients.
    Allahloubi NMA; Zekri AN; Ragab M; Mohanad M; Ahmed OS; Eid S; Ghareeb M; Gouda I; Bahnassy AA
    Biochem Genet; 2022 Dec; 60(6):1963-1985. PubMed ID: 35182276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Harvey V; Neven P; Arnould L; Maibach R; Price KN; Coates AS; Goldhirsch A; Gelber RD; Pagani O; Viale G; Rae JM; Regan MM;
    Breast Cancer Res Treat; 2015 Dec; 154(3):543-55. PubMed ID: 26590813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
    Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
    J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.